BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26834212)

  • 1. Clinical Characteristics and Cytokine Profiles of Organizing Pneumonia in Patients with Rheumatoid Arthritis Treated with or without Biologics.
    Kawasumi H; Gono T; Tanaka E; Kaneko H; Kawaguchi Y; Yamanaka H
    J Rheumatol; 2016 Apr; 43(4):738-44. PubMed ID: 26834212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
    Tang CH; Yu F; Huang CY; Chen DY
    Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.
    Gerhold K; Richter A; Schneider M; Bergerhausen HJ; Demary W; Liebhaber A; Listing J; Zink A; Strangfeld A
    Rheumatology (Oxford); 2015 Oct; 54(10):1858-66. PubMed ID: 26001633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results.
    Lau AN; Thorne JC; Movahedi M; Rampakakis E; Cesta A; Li X; Couto S; Sampalis J; Bombardier C;
    J Rheumatol; 2019 Aug; 46(8):874-886. PubMed ID: 30988121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
    Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
    Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial.
    Nguyen MTT; Lindegaard H; Hendricks O; Jørgensen CS; Kantsø B; Friis-Møller N
    J Rheumatol; 2017 Dec; 44(12):1794-1803. PubMed ID: 28966211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis.
    Fiehn C; Zinke S; Haas JS; Meise D; Theil J; Gurrath M; Orzechowski HD
    Z Rheumatol; 2023 Nov; 82(9):739-753. PubMed ID: 36757417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
    Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients.
    Park EH; Shin A; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
    Joint Bone Spine; 2021 Jan; 88(1):105057. PubMed ID: 32711117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study.
    Glinatsi D; Heiberg MS; Rudin A; Nordström D; Haavardsholm EA; Gudbjornsson B; Østergaard M; Uhlig T; Grondal G; Hørslev-Petersen K; van Vollenhoven R; Hetland ML
    Trials; 2017 Apr; 18(1):161. PubMed ID: 28376912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting.
    Lau AN; Wong-Pack M; Rodjanapiches R; Ioannidis G; Wade S; Spangler L; Balasubramanian A; Pannacciulli N; Lin CJF; Roy-Gayos P; Bensen WG; Bensen R; Adachi JD
    J Rheumatol; 2018 Feb; 45(2):170-176. PubMed ID: 29142041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
    Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
    Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
    Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
    Gabay C; Riek M; Scherer A; Finckh A;
    Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL.
    Nicholls D; Barrett R; Button P; Truman M; Bird P; Roberts L; Tymms K; Littlejohn G; Griffiths H
    Intern Med J; 2018 Oct; 48(10):1185-1192. PubMed ID: 29968400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of residential area on the management of rheumatoid arthritis patients initiating their first biologic DMARD: Results from the Ontario Best Practices Research Initiative (OBRI).
    Movahedi M; Joshi R; Rampakakis E; Thorne C; Cesta A; Sampalis JS; Bombardier C;
    Medicine (Baltimore); 2019 May; 98(20):e15517. PubMed ID: 31096451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
    Choy E; Aletaha D; Behrens F; Finckh A; Gomez-Reino J; Gottenberg JE; Schuch F; Rubbert-Roth A
    Rheumatology (Oxford); 2017 May; 56(5):689-697. PubMed ID: 27550301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.